Tesamorelin for Athletic Recovery
Research, mechanism, dosing, and effectiveness of Tesamorelin for athletic recovery.
Quick Answer
GH supports recovery from exercise.
Evidence Level
FDA Approved
Typical Dose
2 mg daily
Results Timeline
Recovery benefits within 2-4 weeks
FDA Status
FDA Approved
How Tesamorelin Works for Athletic Recovery
Growth hormone promotes tissue repair.
About Athletic Recovery
Faster recovery from intense exercise and physical training.
Research Evidence
FDA approved based on trials showing 15-20% reduction in visceral adipose tissue over 26 weeks. March 2025: FDA approved new F8 formulation (Egrifta WR) with weekly reconstitution, reducing patient burden. CROI 2025 data highlighted limitations of BMI for cardiovascular risk assessment in HIV patients.
Dosing for Athletic Recovery
Recommended Dose
2 mg daily
Frequency
Once daily
Administration
Subcutaneous injection
Duration
Indefinite for approved indication
Note: FDA-approved dose is 2 mg (original) or 1.28 mg (F8/Egrifta WR formulation). Inject subcutaneously in abdomen. F8 requires weekly reconstitution vs daily.
What to Expect
Initial adjustment period. Some users may notice subtle changes.
Early benefits often become noticeable. Continue consistent use.
Most users report meaningful improvements by this point.
Full effects typically realized. Reassess and adjust as needed.
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Injection site reactions (common)
- •Joint pain
- •Peripheral edema
- •Pain in extremities
- •Muscle pain
- •Increased diabetes risk
Frequently Asked Questions
Does Tesamorelin help with athletic recovery?
GH supports recovery from exercise.
How does Tesamorelin work for athletic recovery?
Growth hormone promotes tissue repair....
What dose of Tesamorelin should I use for athletic recovery?
2 mg daily
How long until I see results?
Recovery benefits within 2-4 weeks
Other Peptides for Athletic Recovery
These peptides are also researched for athletic recovery.
Ipamorelin
Clinical TrialsA selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin. Considered one of the safest GHRPs.
MK-677
Clinical TrialsAn orally active growth hormone secretagogue that mimics ghrelin. Although technically not a peptide, it is frequently discussed alongside GH peptides due to similar effects.
CJC-1295 (No DAC)
Clinical TrialsA synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates GH release from the pituitary. Often combined with a GHRP like Ipamorelin for synergistic effects.
GHRP-6
Clinical TrialsOne of the first synthetic GH secretagogues developed. Strongly stimulates GH release and significantly increases appetite through ghrelin receptor activation.